PTX3 and prostate carcinoma: In line with its antitumoral activity, PTX3 immune reactivity that is normally abundant in the prostate gland has been shown to disappear in tumor biopsies taken from high-grade intraepithelial neoplasias and prostatic adenocarcinomasin experimental models of prostate cancer (Ronca et al., 2013).